# Ignace Vergote

Source: https://onco.cc/people/ignace-vergote/  
OnCo record `ignace-vergote` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer.

## Summary

Ignace Vergote was principal investigator of EORTC 55971, which showed neoadjuvant chemotherapy followed by interval surgery is non-inferior to primary surgery in advanced ovarian cancer with less morbidity, and of innovaTV 301, in which tisotumab vedotin improved survival in recurrent cervical cancer. He founded the ENGOT network of European gynaecological trial groups and has led more than 30 phase 3 trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: ovarian; cervical; adc; cooperative-group
- Role: Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT
- Specialisms: Gynaecologic oncology; Neoadjuvant chemotherapy; Antibody-drug conjugates; Cervical cancer

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Vergote%20I%5BAuthor%5D%20ovarian%20OR%20cervical

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [Tissue factor](https://onco.cc/targets/tissue-factor/)
- drugs: [Tisotumab vedotin](https://onco.cc/drugs/tisotumab-vedotin/)
- institutions: [UZ Leuven / Leuven Cancer Institute](https://onco.cc/institutions/uz-leuven/)
- trials: [innovaTV 301 / ENGOT-cx12 / GOG-3057](https://onco.cc/trials/innovatv-301/)

---
JSON: https://onco.cc/api/v1/entities/ignace-vergote.json